Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

16.77
+0.17001.02%
Volume:3.29M
Turnover:55.75M
Market Cap:1.99B
PE:-14.48
High:17.50
Open:16.70
Low:16.63
Close:16.60
Loading ...

Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)

Insider Monkey
·
09 Oct 2024

Exploring High Growth Tech Stocks In The US October 2024

Simply Wall St.
·
03 Oct 2024

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
25 Sep 2024

BRIEF-Arcutis Says New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement Of Atopic Dermatitis In Individuals With Diverse Skin Types

Reuters
·
25 Sep 2024

New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

THOMSON REUTERS
·
25 Sep 2024

Arcutis Biotherapeutics Says US FDA Accepts Supplemental New Drug Application for Psoriasis Treatment

MT Newswires Live
·
24 Sep 2024

BRIEF-FDA Accepts Arcutis’ Supplemental New Drug Application For Zoryve

Reuters
·
24 Sep 2024

Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of May 22, 2025

THOMSON REUTERS
·
24 Sep 2024

FDA Accepts Arcutis’ Supplemental New Drug Application for Zoryve® (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

THOMSON REUTERS
·
24 Sep 2024

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Simply Wall St.
·
23 Sep 2024

Arcutis Biotherapeutics Says Phase 3 Data Confirm Zoryve's Efficacy in Atopic Dermatitis

MT Newswires Live
·
19 Sep 2024

Arcutis Biotherapeutics Inc - Zoryve Cream 0.15% Improves Atopic Dermatitis With Favorable Safety

THOMSON REUTERS
·
19 Sep 2024

Arcutis Announces Publication of Zoryve® (Roflumilast) Cream 0.15% Pivotal Results From Phase 3 Integument-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

THOMSON REUTERS
·
19 Sep 2024

Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals

TIPRANKS
·
19 Sep 2024